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Recent data suggest that the chemokine receptor CXCR3 is functionally involved in ﬁbro-
proliferative disorders, including liver ﬁbrosis. Neoangiogenesis is an important pathophys-
iological feature of liver scarring, but a functional role of angiostatic CXCR3 chemokines in
this process is unclear. We therefore investigated neoangiogenesis in carbon tetrachloride
(CCl4)-induced liver ﬁbrosis in Cxcr3
2/2 and wildtype mice by histological, molecular, and
functional imaging methods. Furthermore, we assessed the direct role of vascular endothe-
lial growth factor (VEGF) overexpression on liver angiogenesis and the ﬁbroproliferative
response using a Tet-inducible bitransgenic mouse model. The feasibility of attenuation of
angiogenesis and associated liver ﬁbrosis by therapeutic treatment with the angiostatic che-
mokine Cxcl9 was systematically analyzed in vitro and in vivo. The results demonstrate that
ﬁbrosis progression in Cxcr32/2 mice was strongly linked to enhanced neoangiogenesis and
VEGF/VEGFR2 expression compared with wildtype littermates. Systemic VEGF overexpres-
sion led to a ﬁbrogenic response within the liver and was associated with a signiﬁcantly
increased Cxcl9 expression. In vitro, Cxcl9 displayed strong antiproliferative and antimigra-
tory effects on VEGF-stimulated endothelial cells and stellate cells by way of reduced
VEGFR2 (KDR), phospholipase Cc (PLCc), and extracellular signal-regulated kinase
(ERK) phosphorylation, identifying this chemokine as a direct counter-regulatory molecule
of VEGF signaling within the liver. Accordingly, systemic administration of Cxcl9 led to a
strong attenuation of neoangiogenesis and experimental liver ﬁbrosis in vivo. Conclusion:
The results identify direct angiostatic and antiﬁbrotic effects of the Cxcr3 ligand Cxcl9 in a
model of experimental liver ﬁbrosis. The amelioration of liver damage by systemic applica-
tion of Cxcl9 might offer a novel therapeutic approach for chronic liver diseases associated
with increased neoangiogenesis. (HEPATOLOGY 2012;55:1610-1619)
T
he pathophysiology of liver ﬁbrosis is a com-
plex biological process which includes features
of abnormal inﬂammatory wound healing, the
deposition of extracellular matrix proteins, and
increased neoangiogenesis.1-3 At advanced stages, liver
ﬁbrosis leads to liver failure, portal hypertension, and
represents the main risk factor for hepatocellular carci-
noma.4 Therefore, novel therapies that target key mol-
ecules involved in ﬁbrosis progression are clinically
warranted.
A chemokine receptor that has been implicated in
many pathophysiological processes of ﬁbroproliferative
disorders, including liver ﬁbrosis, is CXCR3.5,6 The
main ligands of this receptor are the interferon-c-in-
ducible chemokines CXCL9, CXCL10, and CXCL11
and the platelet-derived chemokine CXCL4 in
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humans. In experimental murine liver ﬁbrosis models,
genetic deletion of Cxcr3 (Cxcr3/) leads to a
reduced hepatic inﬁltration of interferon-c-positive
T-cells,7 which are considered part of an antiﬁbrotic
immune response.8 These results are congruent with
the main role of CXCL9 for transendothelial migra-
tion of T helper 1 (Th1)-polarized cells into the liver.
9
Furthermore, Cxcr3 has been shown to be important
for recruitment of CD4þCD25þ T regulatory cells
into the liver, which might limit inﬂammatory hepatic
injury.10,11 In vivo, the absence of Cxcr3 leads to pro-
nounced liver ﬁbrosis7 and an exacerbated liver dam-
age after Concanavalin A administration.11 These ﬁnd-
ings are in line with previous studies showing an
enhanced ﬁbrogenic response of Cxcr3-deﬁcient mice
in the lung12 and the kidney.13
Neoangiogenesis and the development of an abnor-
mal angioarchitecture in the liver are strongly linked
with progressive ﬁbrogenesis, although the direct inter-
action between both processes is not yet fully under-
stood.14 Among molecules involved in angiogenesis,
vascular endothelial growth factor (VEGF) has been
identiﬁed to play potent angiogenic as well as proﬁbro-
genic role during liver ﬁbrogenesis.2,15 In line with these
ﬁndings, receptors for VEGF (VEGFR) are expressed in
liver sinusoidal endothelial and stellate cells.14 Interest-
ingly, the CXC family of chemokines is also known to
be crucially involved in angiogenesis. Members of the
CXC family that contain an ELR motif (ELRþ chemo-
kines) promote angiogenesis, whereas ELR chemo-
kines, which are all ligands of CXCR3, antagonize the
formation of new blood vessels.5,16 Notably, the angio-
static CXCR3 ligand CXCL4 directly interferes with
VEGF signaling in human cells.17 In light of the strong
interplay between angiogenesis and ﬁbrosis, these angio-
static features support that this family of chemokines
might include important regulators of chronic liver dis-
eases. This hypothesis is supported by earlier studies
demonstrating an amelioration of experimental pulmo-
nary angiogenesis by systemic administration of Cxcl10
and Cxcl11 in mice,16,18 but no studies in experimental
liver diseases have yet been performed.
Based on this scientiﬁc background, we aimed at
characterizing neoangiogenesis in Cxcr3/ and wild-
type (WT) mice after carbon tetrachloride (CCl4)-
induced liver ﬁbrosis and to investigate the feasibility
of modifying neoangiogenesis and ﬁbrogenesis by sys-
temic administration of the angiostatic Cxcr3 ligand
Cxcl9 in vivo.
Materials and Methods
In Vivo Experiments. C57BL/6 WT, Cxcr3/,
and their littermates (backcrossed for more than 10
generations onto the C57BL/6 background)7 as well as
VEGF bitransgenic (Pax8-rtTA/(tetO)7-VEGF) mice
19
were maintained in a pathogen-free environment. All in
vivo experiments were performed following approval by
the state Animal Protection Board. Cxcr3/ and WT lit-
termates were injected with CCl4 (Merck; 0.6 mL/kg of
body weight) intraperitoneally for 6 weeks to induce liver
ﬁbrosis. In a separate experiment, recombinant Cxcl9 (1
lg; Biomol, Germany) or vehicle was administered to
C57BL/6 WTmice concomitantly with or without CCl4
treatment for 6 weeks. The in vivo dose of Cxcl9 was
selected based on experience of other chemokines in
models of lung ﬁbrosis.16,18 Mice were sacriﬁced for anal-
ysis 3 days after the last CCl4 injection. VEGF bitrans-
genic mice were generated by crossbreeding heterozygous
Pax8-rtTA mice, which express the reverse tetracycline de-
pendent transactivator (rtTA) under control of the Pax
promoter, with homozygous (tetO)7-VEGF mice, which
synthesize VEGF under the control of a tetracycline re-
sponsive promoter. VEGF overexpression in these mice
was induced with doxycycline (Dox, 1 mg/mL) orally
administered for 14 or 28 days, respectively. Although
these mice overexpress VEGF under a kidney-speciﬁc
promoter, they have strongly increased systemic levels of
VEGF (Supporting Fig. 4), which have an impact on
other organs of the animals. WT littermates with or
without Dox administration were used as controls.
Quantiﬁcation of Liver Fibrosis. Liver scarring
was determined by quantitative analysis of Sirius red
staining of liver sections (3 lm). The area of positive
Sirius red staining was quantiﬁed using National Insti-
tutes of Health (NIH) ImageJ software (http://rsbweb.
nih.gov/). Hepatic concentrations of the collagen-
speciﬁc amino acid hydroxyproline were assessed col-
orimetrically as described.20
Quantiﬁcation of Angiogenesis. Angiogenesis was
assessed by staining of von Willebrand factor (vWF),
CD34, and CD31 (PECAM-1) as well as by Sono-
Vue-enhanced ultrasound. Cryosections of liver tissue
were stained with a monoclonal rat antimouse CD31
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antibody (BD Biosciences) as well as with a monoclo-
nal goat antihuman vWF antibody (C-20, Santa Cruz)
followed by a suitable secondary antibody conjugated
with Alexa ﬂuor 488 (Invitrogen) to highlight micro-
vessels. Sections were counterstained for nuclei with
Vectashield Mounting Medium with DAPI (Vector
Laboratories). Microvessel density (MVD) was deter-
mined by counting the CD31 positive vessels in three
high-power ﬁelds (100 magniﬁcation) from areas of
highest vascularization.21 The vWF-positive cells were
quantiﬁed using NIH ImageJ software. Immunohisto-
chemical staining of the monoclonal rat antimouse
CD34 antibody (BD Biosciences) was performed on
deparafﬁnized tissue sections using a routine avidin-
biotin-immunoperoxidase technique (Vectastain ABC
kit, Vector Laboratories). Before incubation with the
primary antibody, tissue sections were subjected to
microwave treatment with Citrate-based Antigen
Unmasking Solution (Vector Laboratories), followed
by a 20-minute cool-down and treatment with 3%
hydrogen peroxide. Angiogenesis-related perfusion was
assessed by two-dimensional SonoVue-enhanced ultra-
sound imaging using a clinical imaging system (Acu-
son S2000, Siemens Healthcare). A multi-D matrix
array transducer was attached to a device and the
acoustic focus was placed on the level of the dorsal
liver capsule. After tail vein injections of mice with 50
lL diluted SonoVue (Bracco; diluted 1:5 with 0.9%
NaCl), imaging in CPS-mode with a rate of 13
frames/sec for 40 seconds was performed. A region of
interest (ROI) was set within the liver and the area
under the curve (AUC) was quantiﬁed for this ROI.
The values were normalized by the AUC of an ROI
placed in the caval vein (Supporting Fig. 1).
In Vivo Molecular Imaging of VEGFR2. Fluores-
cence labeling of VEGFR2 antibody was performed
with VivoTag-S680 (VisEn Medical) by way of NHS
ester. Normal goat IgG antibody (AF644 and AB-108-
C, R&D Systems) was used as isotype control. Anti-
bodies were diluted in 200 lL carbonate/bicarbonate
buffer to concentrations of 1 mg/mL and incubated
each with 6 lL VivoTag-S680 for 1 hour at room tem-
perature. Nonreacted VivoTag-S680 ﬂuorophores were
separated from labeled antibodies by size exclusion
chromatography with fast protein liquid chromatogra-
phy (FPLC) (A¨KTApuriﬁer 10, GE Healthcare). Sub-
sequently, VivoTag-S680 labeled VEGFR2 and IgG
probes were injected in CCl4-treated Cxcr3
/ and
WT littermates by way of a tail vein catheter (100
lL). Probe enrichment in the liver was determined 6
hours after probe injection using ﬂuorescence molecu-
lar tomography (FMT 2500; Visen). Additionally, low-
dose lCT scans (TomoScope DUO, CT Imaging)
were performed and coregistered to the 3D FMT data
in order to add anatomical information.
Intrahepatic Protein and Gene Expression. Isola-
tion of total protein and RNA from snap-frozen liver
tissue samples were performed as described.20 Intrahe-
patic Cxcl9, Cxcl10, Cxcl1, and VEGF concentrations
were determined using mouse enzyme-linked immuno-
sorbent assay (ELISA) kits (R&D Systems), following
the manufacturer’s instructions. Quantitative reverse-
transcription polymerase chain reaction (RT-PCR) was
carried out for VEGF, VEGFR1, VEGFR2, and Col1a1
with Assays-on-Demand (Applied Biosystems).
Analysis of a-Smooth Muscle Actin (a-SMA). Wes-
tern blotting of a-SMA on liver protein extracts was
performed as described.20 GAPDH was used as a load-
ing control.
Intracellular Interferon-c (Ifn-c) Detection by
Flow Cytometry. Flow cytometric analysis of Ifn-c in
the cytoplasm of T cells was performed as described.7
In Vitro Experiments. Isolation and culture of pri-
mary liver cells from CCl4-treated and untreated mice
was performed as described by Taura et al.22 The
SV40-transformed mouse endothelial cell line (SVEC)
and the stellate cell line GRX20 were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) with 4.5
g/L glucose (PAA Laboratories) and 10% heat-inacti-
vated fetal calf serum (FCS). For chemokine stimula-
tion, cells were starved in DMEM containing 0.5%
FCS (starving medium) for 16 hours and stimulated
with recombinant mouse VEGF164 (20 ng, Biomol) in
the presence or absence of recombinant mouse Cxcl9
(100 ng, Biomol) for 10 minutes. Western blots of
phosphorylated and total VEGFR2 (KDR, kinase
insert domain-containing receptor), PLCc (phospholi-
pase Cc), extracellular signal-regulated kinase (ERK),
and c-Jun N-terminal kinase (JNK) (all antibodies
from Cell Signaling Technology) were performed.
Cell Migration Assay. The chemotaxis of endothe-
lial cells to VEGF and its repression by Cxcl9 was
assessed in a modiﬁed Boyden chamber system. Endo-
thelial cells (1  104) were placed in the upper com-
partment in starving medium and were exposed to
recombinant mouse VEGF164 (20 ng, Biomol) alone
or in combination with recombinant mouse Cxcl9
(100 ng) in the lower compartment. After 4 hours of
incubation, cell migration was analyzed by counting
cells of three random high-power ﬁelds (100 magni-
ﬁcation). All experiments were performed in
quadruplicate.
Cell Proliferation Assay. For quantiﬁcation of en-
dothelial and stellate cell proliferation a
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chemiluminescent immunoassay based on the measure-
ment of bromodeoxyuridine (BrdU) incorporation dur-
ing DNA synthesis was used (Cell Proliferation ELISA,
BRDU, Roche Applied Science).20 Brieﬂy, cells (0.5 
104) were cultured in starving medium for 16 hours
and stimulated for 24 hours with VEGF and costimu-
lated with Cxcl9 as mentioned. After BrdU labeling, ﬁx-
ation, and DNA denaturation, the BrdU incorporation
was quantiﬁed by measuring the subsequent substrate
reaction. For studying sinusoidal endothelial cell / he-
patic stellate cell interactions in response to Cxcl9, we
performed experiments with conditioned medium. Cul-
tured endothelial cells were stimulated with or without
VEGF 6 Cxcl9 (see above) for 24 hours and the super-
natant was harvested for cell migration and proliferation
experiments of stellate cells.
Assessment of Cell Proliferation and Migration in
a Scratch Assay. The composite of endothelial cell
migration and proliferation were performed in a
scratch assay. After the cell culture was conﬂuent in 6-
well plates, a straight scratch with a pipette tip (blue,
Gilson) was created on the cell monolayer. Subse-
quently, the cells were stimulated for 24 hours with
VEGF in the presence or absence of recombinant
Cxcl9. To quantify cell migration and proliferation the
width of the scratch was recorded and measured digi-
tally (100 magniﬁcation) before and after stimulation
in order to calculate the ratio.
In Vitro Matrigel Angiogenesis Assay. To study
angiogenesis, the process of blood vessels, in vitro, a
Matrigel Basement Membrane Matrix (BD Bioscien-
ces) was used. Endothelial cells (5  104) were plated
on Matrigel in starving medium and stimulated for 8
hours with VEGF and costimulated with Cxcl9 as
mentioned. The tube formation under these conditions
was quantiﬁed by measuring the number of these cap-
illary-like structures.
Statistical Analysis. Results are depicted as mean
6 standard error of the mean (SEM). Statistical signif-
icance was assessed by two-way analysis of variance fol-
lowed by Student t test, with Welch’s correction in
case of unequal variances. Statistical analyses were per-
formed using GraphPad Prism 5.
Results
Lack of Cxcr3 Is Associated with Increased Neoan-
giogenesis in Experimental Liver Fibrosis. We ﬁrst
assessed the density of intrahepatic blood vessels in
WT mice with or without administration of CCl4 for
6 weeks.
Development of liver ﬁbrosis after CCl4 challenge
was associated with an increased number of CD31 and
vWF-positive vessels and augmented hepatic messenger
RNA (mRNA) expression of VEGF and VEGFR2,
conﬁrming a link between angiogenesis and progres-
sion of liver ﬁbrosis.22 Treatment with CCl4 also
increased hepatic protein concentrations of angiogenic
(Cxcl1) and angiostatic (Cxcl9, Cxcl10) chemokines
(Supporting Fig. 2). Notably, Cxcr3/ mice displayed
a further signiﬁcantly higher blood vessel density
within the liver compared with their WT littermates
after CCl4 treatment (Fig. 1A,B). Aberrant angiogene-
sis in Cxcr3/ mice was also reﬂected by strongly
Fig. 1. Association of neoangio-
genesis with experimental liver ﬁ-
brosis. Vessel density was
assessed by counting CD31-posi-
tive vessels (200 magniﬁcation)
after immunoﬂuorescence staining
of CD31 (A) and vWF (B). The
administration of CCl4 for 6 weeks
led to a signiﬁcantly increased
number of CD31 and vWF-positive
vessels in Cxcr3/ mice com-
pared with their WT littermates
(n ¼ 8 mice per group).
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increased levels of VEGF and VEGFR2 mRNA expres-
sion (Fig. 2A,B). Interestingly, the increased expression
of VEGF receptors in Cxcr3/ mice was only evident
for VEGFR2, but not for VEGFR1 (data not shown).
Given the importance of the VEGF pathway in angio-
genesis,14 we established a ﬂuorescence molecular to-
mography (FMT) detection method for assessment of
VEGFR2 expression in vivo. The FMT conﬁrmed a
higher level of VEGFR2 in the livers of Cxcr3/
mice compared with untreated mice and WT litter-
mates after 6 weeks of CCl4 treatment (Fig. 2C).
Enhanced overall neoangiogenesis in Cxcr3/ mice
was further conﬁrmed by increased perfusion of the
liver by contrast-enhanced ultrasound (Supporting Fig.
3), supporting a high vessel density and a strong
proangiogenic phenotype of Cxcr3/ mice.
VEGF Overexpression Is Associated with Aug-
mented Fibrogenesis and Increased Concentrations of
Chemokines. In light of the increased VEGF/VEGFR2
expression in CCl4-treated mice, we next evaluated the
direct effects of VEGF on the liver. VEGF bitransgenic
mice received doxycycline for 2 and 4 weeks, resulting
in strongly increased serum concentrations of VEGF
in these animals (Supporting Fig. 4A). Under these ex-
perimental conditions, overexpression of VEGF for 4
weeks was associated with increased new vessel forma-
tion within the liver (Supporting Fig. 4B) and
increased hepatic collagen deposition (Sirius red stain-
ing, Fig. 3A). In line with these changes, overexpres-
sion of VEGF also resulted in a time-dependent
increase of hydroxyproline, a collagen-speciﬁc amino
acid, and Col1a1 mRNA within the liver (Fig. 3B,C).
As depicted in Fig. 2E,F, overexpression of VEGF was
also associated with altered hepatic levels of Cxc che-
mokines. As in CCl4-treated mice (Supporting Fig. 2),
the angiogenic chemokine Cxcl1 (Supporting Fig. 4C)
and the angiostatic chemokine Cxcl9 (Fig. 3D) were
highly abundant within the liver in response to VEGF
overexpression.
Angiostatic Chemokine Cxcl9 Directly Abrogates
VEGF Effects In Vitro. Because the in vivo results
suggested a close association between VEGF pathways
and the expression of chemokines, we next assessed the
direct effects of the angiostatic chemokine Cxcl9 on
VEGF-mediated effects on endothelial cells and stellate
cells in vitro. Both cell types are considered to be
involved in neoangiogenesis within the liver14 and
express both Cxcl9 and its receptor Cxcr3 (Supporting
Fig. 5A,B). As depicted in Fig. 4A,B, Cxcl9 signiﬁ-
cantly abrogated the proliferative and migratory
response of VEGF on endothelial cells. We next
assessed direct functional aspects of Cxcl9 on angio-
genesis in a Matrigel assay. As shown in Fig. 4C,
Cxcl9 indeed strongly abrogated endothelial network
formation, supporting its direct involvement in
VEGF-induced vessel formation. Furthermore, Cxcl9
inhibited the scratch closure in a functional scratch
assay, which is also considered as a combination of
proliferation and migration of endothelial cells (Sup-
porting Fig. 5C). Importantly, the inhibitory effects of
Cxcl9 were also found in primary sinusoidal endothe-
lial cells isolated from livers of CCl4 damaged animals
(Fig. 5A,B), supporting the relevance of our ﬁndings
for the injury model used in our study. On a
Fig. 2. Increased neoangiogenesis in
Cxcr3/ mice is associated with a signiﬁ-
cantly increased mRNA expression of VEGF
(A) and VEGFR2 (B) compared with their
WT littermates. The augmented expression
of VEGFR2 in Cxcr3/ mice was con-
ﬁrmed in vivo by ﬂuorescence molecular
tomography using radiolabeled antibodies
against VEGFR2 (C) (see Materials and
Methods for details). *P < 0.05.
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molecular level, the effects of Cxcl9 were associated
with a reduced phosphorylation of VEGFR2 (KDR),
its downstream mediator PLCc, JNK, and ERK in pri-
mary endothelial cells (Fig. 5C), supporting earlier
results of antiangiogenic chemokines on the VEGF sig-
naling pathway.17 Cxcl9 also reduced the VEGF-
induced proliferation of stellate cells (Supporting Fig.
6A), which was also associated with a reduced phos-
phorylation of KDR, JNK, and ERK (Supporting Fig.
6B). As endothelial and stellate cells are both consid-
ered to play a pivotal role during liver neoangiogenesis,
we also evaluated the direct interaction between these
cell types with and without treatment of Cxcl9.
Indeed, conditioned medium from VEGF stimulated
endothelial cells induced the proliferation and migra-
tion of stellate cells in vitro, which was strongly
reduced by concomitant treatment of endothelial cells
with Cxcl9 (Supporting Fig. 6C).
Cxcl9 Inhibits Neoangiogenesis in the Liver In
Vivo. In the light of these in vitro data, we hypothe-
sized that systemic administration of Cxcl9 might also
modulate CCl4-induced hepatic neoangiogenesis
in vivo. Indeed, daily administration of Cxcl9 concom-
itantly to CCl4 strongly inhibited the formation of
new blood vessels compared with vehicle-treated mice.
The difference between Cxcl9 und vehicle-treated mice
was evident by quantiﬁcation of CD31-positive cells
(Fig. 6A) as well as vWF-positive cells (Supporting
Fig. 7). Furthermore, as determined by contrast-
enhanced ultrasound, the microvascular perfusion of
the liver was signiﬁcantly reduced in Cxcl9-treated
mice compared with vehicle-treated mice, supporting a
reduced density of vessels in the livers of these mice
(Fig. 6B). In line with the direct interaction between
Cxcl9 and VEGF pathways in vitro, the antiangiogenic
properties of Cxcl9 were also linked to a strong
decrease in VEGF protein levels within the liver
in vivo (Supporting Fig. 8A).
Treatment of Mice with Cxcl9 Ameliorates Liver
Fibrosis In Vivo. Importantly, alongside reduced neo-
angiogenesis, mice treated with Cxcl9 also had a
strongly reduced severity of liver ﬁbrosis compared
with vehicle-treated mice (Fig. 7A). This difference
was evident after quantiﬁcation of Sirius red-stained
Fig. 3. The systemic overexpression
of VEGF for 4 weeks leads to an aug-
mented deposition of collagen (Sirius
red staining, magniﬁcation 100) (A).
The increased ﬁbrogenic response in
VEGF overexpression animals was con-
ﬁrmed by a time-dependent increase
of the collagen-speciﬁc amino acid
hydroxyproline (B) and the mRNA
expression of Col1a1 (C). Furthermore,
VEGF overexpression is associated with
increased levels of the chemokine
Cxcl9 (D) within the liver (n ¼ 8 mice
per group). *P < 0.05, **P < 0.01,
***P < 0.001.
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liver tissues (Fig. 7B), biochemical measurement of he-
patic hydroxyproline contents (Fig. 7C), and by assess-
ment of intrahepatic Col1a1 mRNA expression (Sup-
porting Fig. 8B). As Cxcl9 might have direct
chemotactic effects on liver inﬁltrating cells, we also
determined the number of Th1-polarized, IFN-c-posi-
tive cells in the livers of Cxcl9 and vehicle-treated
mice. However, the number of IFN-c-positive cells
was not different between the groups (Supporting Fig.
8C), arguing against a major inﬂuence of the immune
system on the phenotype observed after Cxcl9 treat-
ment. Instead, the content of a-SMA in the liver was
Fig. 4. In vitro, Cxcl9 counteracts VEGF-mediated endothelial cell
(SVEC) proliferation (A) and migration (B). Furthermore, Cxcl9 inhibits
the endothelial cell network formation in a Matrigel assay (C). *P <
0.05, **P < 0.01, ***P < 0.001.
Fig. 5. Cxcl9 does inhibit primary liver sinusoidal endothelial cell
proliferation (A) and migration (B) after isolation of the cells from liv-
ers challenged with CCl4 in vivo. The in vitro effects of Cxcl9 are medi-
ated by strong repression of phosphorylation of VEGFR2 (KDR) and its
downstream modulator PLCc, suggesting a direct effect of the chemo-
kine on the VEGF signaling cascade. Furthermore, Cxcl9 inhibits phos-
phorylation of JNK and ERK (C). **P < 0.01, ***P < 0.001.
Fig. 6. In vivo inhibition of
angiogenesis by systemic Cxcl9.
The angiostatic potential of Cxcl9
was validated in the experimental
liver ﬁbrosis model by CD31 stain-
ing (magniﬁcation 200) (A).
These results are supported by
reduced perfusion of the liver as
determined by contrast-enhanced
ultrasound imaging (B) (see Materi-
als and Methods for details). *P <
0.05, *** P < 0.001.
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strongly reduced by Cxcl9 treatment (Fig. 7D), suggest-
ing that a main effect of Cxcl9 in vivo is the modulation
of stellate cell activation alongside with reduced neoan-
giogenesis and endothelial cell inhibition.
Discussion
In the current study we provide evidence that the
Cxcr3 chemokine system is an important modulator of
neoangiogenesis in the murine liver and that the Cxcr3
ligand Cxcl9 has the potential to ameliorate neoangio-
genesis and liver ﬁbrosis in vivo.
In recent studies we demonstrated that mice deﬁ-
cient in the chemokine receptor Cxcr3 are more prone
to liver ﬁbrosis in different experimental models.7
These results were in line with earlier ﬁndings of the
importance of Cxcr3 in models of pulmonary and re-
nal ﬁbrosis.12,13 The effects of Cxcr3 ligands in liver
disease models were mainly explained by reduced
recruitment of Th1-polarized or regulatory T
cells.7,10,11 Furthermore, a direct inhibitory effect of
CXCL9 on collagen secretion of stellate cells was iden-
tiﬁed.7 However, another important feature of Cxcr3
ligands is their strong angiostatic function16,23 and
their close correlations to VEGF concentrations in
vivo.24 These results, together with the emerging
knowledge of the importance of angiogenesis in
chronic liver diseases,14 motivated our interest to assess
the functional role of the Cxcr3 chemokine system in
angiogenesis during experimental liver damage.
In the ﬁrst set of experiments we conﬁrmed that an
increased number of vessels within the liver is a char-
acteristic feature of experimental liver ﬁbrosis. In the
CCl4 model, vessel formation was associated with
strong expression of the pivotal proangiogenic growth
factor VEGF and its receptor VEGFR2, which have
been earlier considered a prerequisite for ﬁbrogenesis
in vivo.25 Notably, all of these features were strongly
augmented in Cxcr3/ mice compared with their
WT littermates, providing the ﬁrst evidence that this
chemokine pathway displays a nonredundant func-
tional role in liver neoangiogenesis. As angiogenic as
well as angiostatic chemokines were induced by CCl4,
we speculate that the increased expression of the Cxcr3
ligands Cxcl9 and Cxcl10 are part of a feedback loop
in response to liver damage. However, as angiogenesis
and ﬁbrosis are considered to develop in parallel in
chronically damaged liver,26 the question of a primary
effect of Cxcr3 ligands on angiogenesis or ﬁbrogenesis
remains obscure at this point. We therefore used a
bitransgenic mouse model with a strong systemic over-
expression of VEGF to further assess the direct impact
of this angiogenic growth factor on liver ﬁbrogenesis
and intrahepatic chemokine expression. VEGF overex-
pression indeed led to a ﬁbrogenic tissue response
within the liver as determined by signiﬁcantly
increased Col1a1 mRNA and hydroxyproline concen-
trations, although frank scar formation was not evident
after 4 weeks by Sirius red staining. Notably, VEGF
overexpression also strongly increased intrahepatic con-
centrations of Cxcl9, suggesting a functional feedback
loop between the molecules. As CXCR3 agonists in
humans have been shown to directly interfere with
VEGF signaling,17,27 we next assessed whether there is
a direct biological interaction between VEGF and
Cxcl9 on target cells. Indeed, Cxcl9 repressed prolifer-
atory and migratory effects as well as tube formation
of VEGF-stimulated endothelial cells. As Cxcl9 does
not directly inhibit VEGF secretion from liver cells
(data not shown), these effects appear to be mediated
by direct interference of Cxcl9 with the VEGF signal-
ing pathway, as described for Cxcl4.27 As endothelial
and stellate cells are considered strong contributors to
Fig. 7. Cxcl9 therapy ameliorates liver ﬁbrosis in vivo. Representa-
tive Sirius red stainings of CCl4-treated WT mice, with a concomitant
administration of vehicle or Cxcl9 (n ¼ 9 per group; 100 magniﬁca-
tion) (A). Reduced ﬁbrosis in Cxcl9-treated mice was evident by a sig-
niﬁcantly lower Sirius red-positive area (B) and decreased
concentrations of hydroxyproline (C). Western blot analysis demon-
strates a reduced a-Sma protein expression in total liver lysates of
Cxcl9-treated mice compared with vehicle-treated mice (D). *P <
0.05, **P < 0.01.
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angiogenesis and ﬁbrogenesis,22,28 we also evaluated
the inhibitory potential of Cxcl9 on the interaction
between these cell types. Indeed, Cxcl9-treated endo-
thelial cells were less potent in inducing stellate cell
migration and proliferation. Because these in vitro
results suggested a possible direct effect of Cxcl9 on
multiple aspects of chronic liver damage, we next
assessed the feasibility of amelioration of liver damage
in vivo by therapeutic application of Cxcl9. Although
such a translational approach has been performed in
lung injury models,18 the use of a chemokine for mod-
ulating chronic liver injury has not yet been systemati-
cally evaluated. In these crucial experiments, therapy
with Cxcl9 indeed led to a reduction of CD31-positive
vessels within the liver. The antiangiogenic changes in the
Cxcl9 treated animals were conﬁrmed by a reduced vascu-
lar liver perfusion as determined by contrast-enhanced
ultrasound. As Cxcl9 is not likely to have substantial
effects on cardiac output, the reduced perfusion can be
considered a marker of reduced vessel density within the
liver. In future studies the ultrasound examination estab-
lished in our study might therefore be used for the longi-
tudinal evaluation of vessel density during experimental
angiostatic therapies.29 It is important to note that inhibi-
tion of angiogenesis by targeting key proangiogenic mole-
cules has been shown to aggravate liver ﬁbrosis under
certain circumstances.30,31 We therefore systematically
assessed the ﬁbrotic phenotype in the Cxcl9-treated mice
compared with vehicle-treated mice. As shown in Fig. 6,
amelioration of angiogenesis in our model was associated
with strongly reduced scar formation in the liver. As we
could not ﬁnd major differences in inﬂammation between
Cxcl9 and vehicle-treated mice, which might as such
inﬂuence angiogenesis,32 the amelioration of liver ﬁbrosis
seems to be primarily due to reduced stellate and endo-
thelial cell activation with a corresponding reduction in
vessel formation. Indeed, other drugs that mainly target
stellate and endothelial cells have also been shown to
improve liver ﬁbrosis in vivo.28,33
Taken together, our ﬁndings present evidence that
the Cxcr3 ligand Cxcl9 is a strong counter-regulatory
molecule of VEGF-driven aberrant liver vascularization
and perfusion in vitro and in vivo. The results describe
novel features of this ELR-negative chemokine within
the liver and set the stage for further evaluation of
Cxcl9 as a potential therapeutic option in liver diseases
associated with enhanced angiogenesis and ﬁbrosis.
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